DCs in lymphoma - Biology and therapeutic aspects

Cytotherapy

Volumn 6, Issue 2, 2004, Pages 138-147

  Schultze, Joachim L ^a   Fiore, F ^a   von Bergwelt Baildon, M ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN IDIOTYPE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NAKED DNA; PEPTIDE DERIVATIVE; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CELL LYSATE; CLINICAL TRIAL; CLONAL ANERGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; EFFECTOR CELL; FOLLICULAR LYMPHOMA; GENETIC TRANSFECTION; GERMINAL CENTER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LYMPHOMA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MEDICAL RESEARCH; MINIMAL RESIDUAL DISEASE; MONOCYTE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PROSTATE CANCER; REVIEW; SIDE EFFECT; T CELL LEUKEMIA; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION; VACCINATION;

EID: 2642576044     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/14653240410006095     Document Type: Review

References (118)

1. Finke J, Ferrone S, Frey A et al. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 1999;20:158-60.
2. Lopez CB, Rao TD, Feiner H et al. Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor infiltrating lymphocytes. Cell Immunol 1998;190:141-55.
3. Hammond KJ, Poulton LD, Palmisano LJ et al. alpha/beta-T cell receptor (TCR) + CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10. J Exp Med 1998;187:1047-56.
4. Terabe M, Matsui S, Noben-Trauth N et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000;1:515-20.
5. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-8.
6. Seo N, Tokura Y, Takigawa M et al. Depletion of IL-10- and TGF bcta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 1999;163:242-9.
7. Schultze JL, Cardoso AA, Freeman GJ, S et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci USA 1995;92:8200-4.
8. Schultze JL, Seamon MJ, Michalak S et al. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997;89:3806-16.
9. Cardoso AA, Schultze JL, Boussiotis VA et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996;88:41-8.
10. Dorfman DM, Schultze JL, Shahsafaei A et al. In vivo expression of B7-1 and B7-2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood 1997;90:4297-306.
11. Gitelson E, Spaner D, Buckstein R et al. T-cell analysis in identical twins reveals an impaired anti-follicular lymphoma immune response in the patient but not in the healthy twin. Br J Haematol 2002;116:122-7.
12. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996;14:1-27.
13. Effros RB, Pawelec G. Replicative senescence of T cells: does the Hayflick Limit lead to immune exhaustion? Immunol Today 1997;18:450-4.
14. Seliger B, Maeurer MJ, Ferrone S. TAP off-tumors on. Immunol Today 1997;18:292-9.
15. Petersson M, Charo J, Salazar-Onfray F et al. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol 1998;161:2099-105.
16. Reichert TF, Rabinowich H, Johnson JT, Whiteside TL. Mechanisms responsible for signaling and functional defects. J Immunother 1998;21:295-306.
17. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994;12:227-57.
18. Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999;5:677-85.
19. Anichini A, Molla A, Mortarini R et al. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999;190:651-67.
20. Menetrier-Caux C, Montmain G, Dieu MC et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998;92:4778-91.
21. Troy AJ, Summers KL, Davidson PJ et al. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998;4:585-93.
22. Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002;100:230-7.
23. Mackey MF, Gunn JR, Ting PP et al. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res 1997;57:2569-74.
24. Grufman P, Karre K. Innate and adaptive immunity to tumors: IL-12 is required for optimal responses. Eur J Immunol 2000;30:1088-93.
25. Colombo MP, Vagliani M, Spreafico F et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996;56:2531-4.
26. Eck SC, Turka LA. Generation of protective immunity against an immunogenic carcinoma requires CD40/CD40L and B7/CD28 interactions but not CD4(+) T cells. Cancer Immunol Immunother 1999;48:336-41.
27. Peguet-Navarro J, Moulon C, Caux C et al. Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. Eur J Immunol 1994;24:884-91.
28. Steinbrink K, Wolfl M, Jonuleit H et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772-80.
29. Ludewig B, Graf D, Gelderblom HR et al. Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur J Immunol 1995;25:1943-50.
30. Allavena P, Piemonti L, Longoni D et al. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol 1998;28:359-69.
31. Buelens C, Verhasselt V, De Groote D et al. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage colony-stimulating factor. Eur J Immunol 1997;27:756-62.
32. Geissmann F, Revy P, Regnault A et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999;162:4567-75.
33. Qin Z, Richter G, Schuler T et al. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998;4:627-30.
34. Fujii S-i, Shimizu K, Koji F et al. Malignant counterpart of myeloid dendritic cell (DC) belonging to acute myelogenous leukemia (AML) exhibits a dichotomous immunoregulatory potential. J Leukoc Biol 2003;73:82-90.
35. +/CD38 primitive haematopoietic progenitors. Br J Haematol 2002;119:115-8.
36. Bourguin-Plonquet A, Rouard H, Roudot-Thoraval F et al. Severe decrease in peripheral blood dendritic cells in hairy cell leukaemia. Br J Haematol 2002;116:595-7.
37. Orsini E, Guarini A, Chiaretti S et al. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res 2003;63:4497-506.
38. Wysocka M, Zaki MH, French LE et al. Sezary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines. Blood 2002;100:3287-94.
39. Ferrari S, Rovati B, Porta C et al. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard- or high-dose chemotherapy plus granulocyte-colony stimulating factor. Cancer Immunol Immunother 2003;52:359-66.
40. Vuckovic S, Kim M, Khalil D et al. Granulocyte colony-stimulating factor increases CD123hi blood dendritic cells with altered CD62L and CCR7 expression. Blood 2003;101:2314-7.
41. + cell-depleted mobilized peripheral blood can serve as a source of potent dendritic cells. Clin Cancer Res 1998;4:2709-16.
42. + cells mobilized into peripheral blood in lymphoma patients. Cytotherapy 2000; 2:95-104.
43. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen pulsed dendritic cells. Nat Med 1996;2:52-8.
44. Taki C, Kitajima S, Sueyoshi K et al. MUC1 mucin expression in follicular dendritic cells and lymphoepithelial lesions of gastric mucosa-associated lymphoid tissue lymphoma. Pathol Int 2002;52:691-701.
45. Liu YJ, Grouard G, de Bouteiller O et al. Follicular dendritic cells and germinal centers. Int Rev Cytol 1996;166:139-79.
46. Shiozawa E, Yamochi-Onizuka T, Yamochi T et al. Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and Pglycoprotein. Pathol Res Pract 2003;199:293-302.
47. Baur, Meuge-Moraw, Michel et al. Prognostic value of follicular dendritic cells in nodular sclerosing Hodgkin's disease. Histopathology 1998;32:512-20.
48. Nussenzweig MC, Steinman RM. Contribution of dendritic cells to stimulation of the murine syngeneic mixed leukocyte reaction. J Exp Med 1980;151:1196--212.
49. Hu X, Chakraborty NG, Sporn JR et al. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cellbased vaccine. Cancer Res 1996;56:2479-83.
50. Nestle FO, Banchereau J, Hart D. Dendritic cells: on the move from bench to bedside. Nat Med 2001;7:761-5.
51. Celluzzi CM, Mayordomo JI, Storkus WJ et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-7.
52. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
53. Murphy G, Tjoa B, Ragde H et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLAA0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-80.
54. Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000;6:2175-82.
55. Yu JS, Wheeler CJ, Zeltzer PM et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61:842-7.
56. Yamanaka R, Abe T, Yajima N et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003;89:1172-9.
57. Morse MA, Deng Y, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-8.
58. Fong L, Hou Y, Rivas A, B et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci 2001;98:8809-14.
59. Timmerman JM, Czerwinski DK, Davis TA et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002;99:1517-26.
60. Reichardt VL, Okada CY, Liso A et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 1999;93:2411-9.
61. Titzer S, Christensen O, Manzke O et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000;108:805-16.
62. Mukherji B, Chakraborty NG, Yamasaki S et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995;92:8078-82.
63. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells. Nat Med 1998;4:328-32.
64. Stevenson GT, Stevenson FK. Antibody to a molecularly-defined antigen confined to a tumour cell surface. Nature 1975;254:714-6.
65. Janeway CA Jr, Sakato N, Eisen HN. Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes. Proc Natl Acad Sci USA 1975;72:2357-60.
66. Bogen B, Malissen B, Haas W Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of Class II molecules. Eur J Immunol 1986;16:1373-8.
67. Campbell MJ, Carroll W, Kon S et al. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J Immunol 1987;139:2825-33.
68. Gricks CS, Rawlings E, Foroni L et al. Somatically mutated regions of immunoglobulin on human B-cell lymphomas code for peptides that bind to autologous major histocompatibility complex Class I, providing a potential target for cytotoxic T cells. Cancer Res 2001;61:5145-52.
69. Bendandi M, Gocke CD, Kobrin CB et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999;5:1171-7.
70. Trojan A, Schultze JL, Witzens M et al. Immunoglobulin framework-derived peptides function as cytotoxic Tcell epitopes commonly expressed in B-cell malignancies. Nat Med 2000;6:667-72.
71. Campbell M, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol 1988;141:3227-33.
72. Kwak LW, Young HA, Pennington RW et al. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective Tcell response. Proc Natl Acad Sci USA 1996;93:10972-7.
73. Gatza E, Okada CY. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol 2002;169:5227-35.
74. Kwak LW, Campbell MJ, Czerwinski DK et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 1992;327:1209-15.
75. Lee MS, Chang KS, Cabanillas F et al. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 1987;237:175-8.
76. Hsu FJ, Caspar CB, Czerwinski D et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 1997;89:3129-35.
77. Barrios Y, Cabrera R, Yanez R et al. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica 2002;87:400-7.
78. Grosse-Wilde H, Krumbacher K, Schuning F et al. Immune transfer studies in canine allogeneic marrow graft donor-recipient pairs. Transplantation 1986;42:64-7.
79. Zeis M, Steinmann J, Petrela E et al. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graftversus-myeloma effects in mice. Bone Marrow Transplant 2001;27:279-85.
80. Massaia M, Borrione P, Battaglio S et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999;94:673-83.
81. Kwak LW, Taub DD, Duffey PL et al. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995;345:1016-20.
82. Stevenson FK, Zhu D, King CA et al. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev 1995;145:211-28.
83. Stevenson FK, Link CJ Jr, Traynor A et al. DNA vaccination against multiple myeloma. Semin Hematol 1999;36:38-42.
84. Syrengelas AD, Levy R. DNA Vaccination against the idiotype of a murine B-cell lymphoma: mechanism of tumor protection. J Immunol 1999;162:4790-5.
85. Hakim I, Levy S, Levy R. A nine-amino acid peptide from IL-1beta augments antitumor immune responses induced by protein and DNA vaccines. J Immunol 1996;157:5503-11.
86. Timmerman JM, Singh G, Hermanson G et al. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res 2002;62:5845-52.
87. Ohashi T, Hanabuchi S, Kato H et al. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus Type 1 tax-coding DNA vaccine. J Virol 2000;74:9610-6.
88. Maier T, Tun-Kyi A, Tassis A et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 2003;102:2338-44.
89. Flamand V, Sornasse T, Thielemans K et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24:605-10.
90. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. Molecular response assessed by PCR is the most important factor predicting failurefree survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 2000;11 Suppl 1:137-40.
91. Nelson EL, Li X, Hsu FJ, Kwak LW et al. Tumorspecific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood 1996;88:580-9.
92. Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 2000;164:4797-803.
93. Hart DN, Hill GR. Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma. Immunol Cell Biol 1999;77:451-9.
94. Thumann P, Luftl M, Moc I et al. Interaction of cutaneous lymphoma cells with reactive T cells and dendritic cells: implications for dendritic cell-based immunotherapy. Br J Dermatol 2003;149:1128-42.
95. Thurner B, Haendle I, Roder C et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced Stage IV melanoma. J Exp Med 1999;190:1669-78.
96. Dhodapkar MV, Steinman RM, Sapp M et al. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J Clin Invest 1999;104:173-80.
97. Lodge PA, Jones LA, Bader RA et al. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a Phase II clinical trial. Cancer Res 2000;60:829-33.
98. Serody JS, Collins EJ, Tisch RM et al. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J Immunol 2000;164:4961-7.
99. Eggert AAO, Schreurs MWJ, Boerman OC et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59:3340-5.
100. Mullins DW, Sheasley SL, Ream RM et al. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003;198:1023-34.
101. Chang AE, Redman BG, Whitfield JR et al. A Phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002;8:1021-32.
102. Yawalkar N, Ferenczi K, Jones DA et al. Profound loss of T cell receptor repertoire complexity in cutaneous T cell lymphoma. Blood 2003;102:4059-66.
103. Thomas R, Chambers M, Boytar R et al. Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res 1999;9:474-81.
104. Frolkis M, Fischer MB, Wang Z et al. Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumors. Cancer Gene Ther 2003;10:239-49.
105. Nair SK, Heiser A, Boczkowski D et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000;6:1011-7.
106. Zeis M, Siegel S, Wagner A et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003;170:5391-7.
107. Gottschalk S, Edwards OL, Sili U et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003;101:1905-12.
108. Edelson RL. Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann NY Acad Sci 2001;941:1-11.
109. + T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity. J Immunol 1999;163:3239-49.
110. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol 2000;18:405-9.
111. Maus MV, Thomas AK, Leonard DG et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002;20:143-8.
112. Thomas AK, Maus MV, Shalaby WS et al. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol 2002;105:259-72.
113. Public, Health, Service. Guideline on infectious disease issues in xenotransplantation. FDA-Department of Health and Human Services 1996:49920-32.
114. Marshall E. Gene therapy. Second child in French trial is found to have leukemia. Science 2003;299:320.
115. von Bergwelt-Baildon MS, Vonderheide RH, Maecker B et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002;99:3319-25.
116. Schultze JL, Michalak S, Seamon MJ et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 1997;100:2757-65.
117. Lapointe R, Bellemare-Pelletier A, Housseau F et al. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen presenting cells that can generate specific T cells. Cancer Res 2003;63:2836-43.
118. Kondo E, Topp MS, Kiem HP et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol 2002;169:2164-71.